ELIXF (Elixxer) Total Receivables: $0.00 Mil (As of Dec. 2025)


What is Elixxer Total Receivables?

Elixxer ELIXF Total Receivables is $0.00 Mil as of Dec. 2025. The stock has 1 warning sign investors should review.

Elixxer's Total Receivables for the quarter that ended in Dec. 2025 was $0.00 Mil.


Elixxer Total Receivables Historical Data

* Premium members only.

The historical data trend for Elixxer's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Elixxer Total Receivables Chart

Elixxer Annual Data
Trend Jun15 Jun16 Sep17 Sep18 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.09 0.04 0.01 0.04 0.00

Elixxer Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 0.04 0.05 0.06 0.00

Elixxer Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of $0.00 Mil mean?
Elixxer (ELIXF) has a Total Receivables of $0.00 Mil as of Dec. 2025. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Elixxer and its competitors.
Is Elixxer's Total Receivables too high?
Elixxer's current Total Receivables is $0.00 Mil.
How does Elixxer's Total Receivables compare to ZTS?
Elixxer's Total Receivables of $0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Drug Manufacturers company?
A good Total Receivables depends on the Drug Manufacturers industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Elixxer and its competitors. Elixxer's current Total Receivables is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elixxer stock overvalued right now?
Elixxer (ELIXF) has a current Total Receivables of $0.00 Mil. The current Total Receivables is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Elixxer (ELIXF), the current Total Receivables is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Elixxer Business Description

Other Exchanges ELXR.H:Canada
Address 200 Bay Street, Suite 3240, Royal Bank Plaza, South Tower, Toronto, ON, CAN, M5J 2J1
Elixxer Ltd is a Canada-based cannabis investment firm in the legal cannabis market. It invests in cannabis-related businesses that are fully licensed for the cultivation, production, and sale of cannabis and cannabis-derived products.